Member Info for Ssccss

It's not £7.1m. It's £8.1m now.

From the final results:
To date, Mint has converted loan notes with principal value of £2,500,000 into shares, leaving convertible loan notes to a value of £9,500,000 outstanding. A conversion notice for a further £900,000 in principal value of loan notes was received from Mint on 23 April 2021 and the corresponding shares will be allotted on or around 4 May 2021, after publication of this report, leaving convertible loan notes to a value of £8,600,000 outstanding.

Hemo would have to pay back 114-120% of £8.1 if they cancel it.

Mint don't want the SP below 1, as then they cannot convert. So either they are selling cautiously or they are waiting until above 3, which is where they last converted. Definitely more selling action today as compared with yesterday.

Thevid, you are so far off the mark :). It certainly is your style to denigrate other posters and your appearance has illustrated my point beautifully.

I'm not lazy. Equally, I'm not here to do other peoples research for them. Why don't you do an adequate competitor analysis? Might encourage some more investors? In fact why don't you focus on positive PR for Hemo, rather than highlighting fault with other posters. It seems a common theme amongst your peers.

I also don't agree about research being dangerous. If more investors has looked into the CLN agreement more closely, many wouldn't be in this situation. Just listening to positive posts on LSE is for sure, a dangerous thing though...unless you like losing money.

Oh dear JHFH. You didn't like my quick Google which was to demonstrate to thise asking questions about competitors, that there is information available if they want to do some research. On the other hand, it seems you must have done lots of research bearing in mind how much you have invested in hemo but still you don't seem to have much solid competitor information either. Many did have trust in Vlad and look where we are...

Hemo aren't even in clinical trials yet, let alone delivering a product. As alluded to before, they are a small company against the clock in terms of competition, so why not focus on one or two products at a time? The company needs to focus on bringing in some revenue in order to develop their other products. Funding is a key issue. Some people are looking at the short/medium term. How do we even get to clinical trials on these products in a decent timeframe without decent funding?

Novartis may already be a competitor. I'm on phone so difficult to do much research.

Couldn't find Hemo but I have only glanced. Novartis and Pfizer in there. So is Janssen

https://bioinformant.com/car-t-companies-the-meteoric-rise-of-cellular-immunotherapies/

List of companies developing CAR T

https://www.nice.org.uk/news/article/nice-recommends-another-revolutionary-car-t-cell-therapy-for-adults-with-lymphoma

Novartis is one of them. This isn't recent news.

https://www.england.nhs.uk/cancer/cdf/car-t-therapy/

Interesting that previous close is showing as 2.65 on LSE today not 2.97 as shown on LSE in Friday.

Worth a pump & dump though ;)

It's about CART-T but not directly about Hemo as it is primarily about therapies which have already been used on patients.

To be fair, Vlad did state in the recent interview that there were competitors who were at similar stages and might beat Hemo to it.

Link to both interviews:
https://total-market-solutions.com/?s=Hemo

Looks like they are leading and hemo are following. Wonder if this could be a contributor to Global co not taking the option.

Porky9, I'm not sure where you have got your figures from. Apparently, Hemo have already drawn down £12m of the loan. So Mint have £8m worth of shares left to convert. I know I keep repeating this but it seems people are not aware of the actual figures and they make a significant difference to the situation. We can't actually determine if they will run out of money as we don't know the future costings as far as I am aware. Additionally, we don't know how Mint are going to be able to convert the rest of their CLNs. So I believe the picture is more uncertain. However, if I have misunderstood, please let me know.

Basically, many here probably want to make some quick money. If that doesn't happen, only LTH will be left and price will drop. OEX SP has proven to be very volatile.

There is always downside. Market is impatient, if things take time which they often do, price will drop. Indian political landscape can be hard going, complicated and times consuming. Getting the gas out of the ground can also be complicated, expensive and time consuming. There are many unknowns at this point but it's looking much better that it was. I think the biggest risk with OEX is more delays and red tape.

By the agents that is...